Millions to benefit as online NHS programmes given green light
The National Institute for Health and Care Excellence (Nice) has conditionally recommended six digital platforms for use by the NHS.
These platforms aim to transform cardiac care delivery, addressing low uptake of traditional programmes and reaching underserved patient groups.
The online programmes offer exercise routines, dietary advice, medication management, psychological support, and some include wearable device integration.
The six platforms will be used on the NHS for three years to gather further evidence on their long-term effectiveness, with a public consultation open until September 3.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Father-of-two, 39, thought stomach pain was from 'dodgy sausage' at BBQ... but it was colon cancer - doctors gave him 'months to live'
The first sign something was wrong for Matt Eamer came just days after a family barbeque, celebrating his son's second birthday. The then 39-year-old father-of-two from Redhill, Surrey, dismissed the sudden 'spiky' stomach pain as food poisoning. 'I was speaking to work colleagues over the first week or two and thought I'd cooked a dodgy sausage,' he said. But his pain escalated quickly. After a rushed trip to A&E he was sent home with anti-nausea medication Buscopan, yet still felt dreadful. His wife Sarah, 41, a doula, took him to East Surrey Hospital where scans revealed a 'big blockage' in his large intestine. Surgeons removed two-thirds of his bowel in an emergency op. 'A few days later they confirmed it was cancer,' Matt said. The diagnosis was stage four bowel cancer. The disease had already spread to his liver and the lining of his abdomen, and further tests revealed a rare BRAF mutation which drives tumours to grow at speed. 'I can still remember the person's voice when she phoned and said, "the plan for your diagnosis has changed… we're talking months not years from a survival point of view",' Matt recalled of the events in September 2020. On his 40th birthday he was told standard chemotherapy had failed and surgeons found the cancer had advanced further. 'It was a very dramatic, movie-like point,' he said. 'It was a pivotal change. They said, "we've gone in, it's gone further, we're going to try these new drugs." My wife Sarah collapsed to the floor.' Matt began fortnightly Cetuximab infusions combined with four daily Encorafenib pills, new immunotherapy drugs approved just months earlier. Designed to buy only 'three to six months', they had a remarkable effect. Within six months, scans showed no trace of cancer. Five years on, he is still clear and continues treatment. 'Hitting five years with stage four is a rarity,' he said. 'You're not on your death bed but you're forced to think about how you spend your time.' In December 2024, he underwent a 14-hour surgery to remove cancerous tissue in his ribcage, followed by heated HIPEC chemotherapy. The disease had already spread to his liver and the lining of his abdomen, and further tests revealed a rare BRAF mutation which drives tumours to grow at speed. Again, scans showed 'things clear.' Matt, who runs his own design agency, continues working and raising his two children. 'The reality is younger people are able to deal with treatments better and live longer, better lives even if it is stage four,' he said. He adds: 'The reality is the 'bucket and spade things', the little moments. I spend more time looking at my kids' faces, taking them to a show or swimming in the sea — they are heightened. 'It means your ability to be present and focus upon what matters is heightened.' To mark five years since his diagnosis, Matt will join Sir Chris Hoy's charity cycle in Glasgow on September 7, raising funds for Bowel Cancer UK. 'It's marking a milestone in a meaningful, positive way,' he said. Bowel cancer, also known as colorectal cancer, is one of the most common cancers in both Britain and the United States. In the UK around 43,000 people are diagnosed every year, while in the US the figure is more than 150,000. It is the third most common cancer worldwide and the second leading cause of cancer deaths. In older age groups incidence is declining thanks to better screening and awareness, yet in younger people rates are rising sharply, a trend baffling doctors. In England cases among those aged 25 to 49 have surged by around 3.6 per cent per year, one of the steepest increases in Europe, while in America rates in under-50s have been rising by about 2.4 per cent annually over the past decade. Outcomes depend heavily on how early the disease is caught. In the UK one-year survival is around 97 per cent if picked up through screening, but just 49 per cent if discovered in an emergency admission, as was the case for Matt. In the US five-year survival is 92 per cent at stage one but only 13 per cent at stage four. Most people with a diagnosis as advanced as Matt's do not reach the five-year mark, making his story unusual. Risk factors include family history, inflammatory bowel disease, obesity, alcohol, smoking, and diets low in fibre and high in red or processed meats. Researchers are also examining the role of ultra-processed foods, though evidence remains inconclusive, and some studies point to gut bacteria toxins such as colibactin, found in food poisoning, as a possible trigger for early-onset cases. Screening programmes remain vital. In the US guidelines now recommend testing from age 45, while in the UK stool tests are currently offered from 56, with pilot schemes lowering the age to 50. Symptoms to watch for include persistent changes in bowel habits, blood in stools, unexplained weight loss, abdominal pain or bloating, and lumps in the abdomen. Doctors stress that catching the disease early saves lives. Patients diagnosed at stage one are several times more likely to survive long term than those at stage four. But as Matt's case shows, advances in treatment—from new targeted drugs to more effective surgery—are beginning to change what is possible, even in the most serious cases. For him, the experience has redefined life. 'The reality isn't bucket-list dolphins—it's the bucket and spade things,' he said.
Glasgow Times
2 hours ago
- Glasgow Times
Type 2 diabetes patients set for major shake-up in care
The health service should move from a one-size-fits-all approach of starting everyone on the same medication, to more personalised care that aims to prevent complications like heart failure and heart attacks, according to new draft guidance from the National Institute for Health and Care Excellence (Nice). This includes making newer type 2 diabetes drugs, known as SGLT-2 inhibitors, a first-line treatment option in a move that could eventually help save tens of thousands of lives. SGLT-2 inhibitors, which include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, are once-a-day tablets that reduce blood sugar levels by helping the kidneys remove glucose, which is passed from the body through urine. However, analysis by Nice found these drugs are under-prescribed. The new guidelines recommend patients who cannot tolerate metformin – the first-choice in type 2 diabetes medication – should start with an SGLT-2 inhibitor on its own. The decision comes after evidence suggested these drugs protect the heart and kidneys as well as controlling blood sugar, Nice said. It is estimated the change could save almost 22,000 lives once uptake reaches 90% of the population. Nice also suggests some groups of patients would also benefit from GLP-1 receptor agonists such as liraglutide or semaglutide sooner, rather than keeping them for the later stages of treatment. Semaglutide, sold under the brand name Ozempic, is licensed in the UK to treat type 2 diabetes, while its other brand – Wegovy – is also used by the NHS to help obese people lose weight. Professor Jonathan Benger, deputy chief executive and chief medical officer at Nice, said: 'This guidance means more people will be offered medicines where it is right to do so to reduce their future risk of ill health. 'This represents a significant evolution in how we approach type 2 diabetes treatment. 'We're moving beyond simply managing blood sugar to taking a holistic view of a person's health, particularly their cardiovascular and kidney health. 'The evidence shows that certain medicines can provide important cardiovascular benefits, and by recommending them as part of initial treatment, we could help prevent heart attacks, strokes and other serious complications before they occur. 'This is particularly important given that cardiovascular disease is the leading cause of death in people with type 2 diabetes.' Around 4.6 million people in the UK are living with diabetes, with nine in 10 of those having type 2. However, it is estimated that a further 1.3 million people may have undiagnosed type 2 diabetes. Nice analysed the records of 590,000 people and found SGLT-2 inhibitors are under-prescribed, particularly to women, older people, and black patients. Prof Benger added: 'The evidence from our analysis is clear. There are prescribing gaps that need to be addressed. 'The guideline update published today will help to increase equitable uptake of SGLT-2 inhibitors, which we know can prevent serious health complications.' Dr Waqaar Shah, chairman of the guideline committee, added: 'We know that SGLT-2 inhibitors are currently under-prescribed, and our health economics analysis shows that people living in the most deprived areas would particularly benefit from universal access to these treatments. 'These recommendations could help reduce health inequalities while providing better outcomes for everyone.' Elsewhere, the draft guidance suggests different treatments for diabetes patients with certain characteristics or health conditions. These include adults with cardiovascular disease, who should be offered a triple therapy including a GLP-1 receptor agonist. Meanwhile, adults diagnosed with type 2 diabetes before 40 should be offered dual therapy before a GLP-1 receptor agonist is considered, while patients with chronic kidney disease should have tailored recommendations based on their kidney function. A public consultation on the new Nice guidelines is open until October 2. Douglas Twenefour, head of clinical at Diabetes UK, said: 'This long-awaited announcement propels type 2 diabetes treatment into the 21st century. 'Boosting access to newer treatments will be transformative for people with type 2 diabetes, while ensuring the UK keeps pace with the global momentum in treating the condition. 'The majority of people with type 2 diabetes are not currently taking the most effective medication for them, putting them at risk of devastating diabetes-related complications. 'Diabetes is a leading cause of cardiovascular disease, and tailoring treatment based on individual risk could protect thousands against heart attacks and kidney disease. 'These guidelines could go a long way to easing the burden of living with this relentless condition, as well as helping to address inequities in type 2 diabetes treatments and outcomes.'
Glasgow Times
2 hours ago
- Glasgow Times
At-home hepatitis C tests identify hundreds with the virus
Officials said more than 100,000 people have ordered at-home hepatitis C tests since the service was launched in May 2023. This includes 15,463 tests ordered in the week after the Infected Blood Inquiry published its final report on May 2024. Hepatitis C often shows no signs until serious damage is done. It can be treated, so testing is key to help you help reduce your risk. #WorldHepatitisDay #HepC🔗 — UK Health Security Agency (@UKHSA) July 28, 2025 Hepatitis C is a virus that is passed on through blood-to-blood contact and infects the liver. The disease is known as a 'silent killer' as some people can live with the virus for many years before realising that they are infected. But the delay in diagnosis can lead to irreparable liver damage, including scarring and cancer. If people test positive they can often be treated by taking antiviral tablets to fight off the virus for several weeks. People who test positive may also be offered a test to see whether any damage has been caused to the liver. Health officials said that 105,998 people have ordered an at-home NHS hepatitis C test online since the service was launched in 2023. Among those diagnosed under the NHS scheme so far, NHS England said that seven in 10 are from deprived communities. And it said that the most common risk factors reported by positive cases include injecting drug use, sharing needles and other drug paraphernalia and a history of prison. It is understood that only a very small number identified after ordering a test online had a positive result after receiving contaminated blood. In May this year NHS England also launched a system which means that people of a certain age who newly register with GP practices in England will be asked if they had a blood transfusion prior to 1996 in a bid to find more victims of the infected blood scandal. The Infected Blood Inquiry, which examined the scandal in depth, recommended that the health service should work to 'find the undiagnosed'. More than 30,000 people in the UK were infected with HIV and hepatitis C after they were given contaminated blood and blood products between the 1970s and early 1990s. And more than 3,000 people have died as a result while survivors are living with lifelong health implications. Professor Meghana Pandit, NHS national medical director, said 'We want to make it easier for people to access care before hidden viruses like hepatitis C cause people serious harm. 'The home testing service is available to everyone, and through targeted outreach to people at higher risk we are helping thousands avoid serious illness and reducing health inequalities in the process. 'If you or someone you know might be at risk, order a free and confidential test today via the NHS hepatitis C testing website – it could save your life.' Sema Mandal, deputy director for blood safety at UK Health Security Agency, said: 'Our data shows that the number of people with hepatitis C in England is continuing to fall, thanks to more people getting tested and taking treatment that clears the virus. 'I'm delighted to hear that 100,000 of the free self-testing kits have already been ordered via NHS online and this should further help us defeat this disease.' Rachel Halford, chief executive of The Hepatitis C Trust, said: 'Reaching 100,000 home tests is an incredible milestone as we push closer towards the elimination of hepatitis C. 'This option of home testing allows people with any concerns to get a free, confidential test without the need to attend a clinic. For many hesitant to access health services, this can act as a lifeline. 'While injecting drug use remains a key risk factor, it is equally important to remember those affected by the infected blood scandal – the most devastating treatment disaster in the history of the NHS. 'If you received a blood transfusion or blood products before 1996, we strongly encourage you to order a test. Even for peace of mind alone, it could be invaluable. Today's treatments are highly effective, simple to take, and come with minimal side effects.'
